Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

90.56 USD -1.48 (-1.61%)
Official Closing Price Updated: 7:39 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 930,100
Open 91.64
Bid (Size) 89.00 (5)
Ask (Size) 92.60 (15)
Prev. Close 92.04
Today's Range 89.32 - 92.52
52wk Range 62.48 - 110.36
Shares Outstanding 211,969,163
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
From ACCESSWIRE
Incyte and MorphoSys Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
From PR Newswire

Performance

YTD
+4.75%
+4.75%
1 Month
+5.02%
+5.02%
3 Month
-0.08%
-0.08%
6 Month
-13.02%
-13.02%
1 Year
+12.33%
+12.33%

More News

Read More
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine
From PR Newswire
Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804
From Business Wire News Releases
Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
From ACCESSWIRE
Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm
From Business Wire News Releases
Incyte to Present at Upcoming Investor Conference
From Business Wire News Releases
Why These Health Care Stocks Are Moving Today
Tags why it's moving Movers Small Cap
From Benzinga
Nasdaq 100 Movers: SGEN, BIDU
Tags Stocks
From Market News Video
Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
From Business Wire News Releases
Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.